<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028873</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-10003-16004</org_study_id>
    <secondary_id>EORTC-16004</secondary_id>
    <secondary_id>ECSG-EORTC-16004</secondary_id>
    <secondary_id>IDBBC-10003</secondary_id>
    <nct_id>NCT00028873</nct_id>
  </id_info>
  <brief_title>R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy</brief_title>
  <official_title>An EORTC-IDBBC/ECSG Phase II Study Evaluating The Role Of The Multi-Drug Resistance (MDR) Reversor, R101933, In Patients With Taxane Refractory Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining&#xD;
      R101933 with paclitaxel or docetaxel may reduce resistance to the drug and allow the tumor&#xD;
      cells to be killed.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining R101933 with either&#xD;
      paclitaxel or docetaxel in treating patients who have metastatic breast cancer that has not&#xD;
      responded to previous chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the activity of R101933 in combination with paclitaxel or docetaxel in terms&#xD;
           of response to treatment and level of clinical benefit in patients with&#xD;
           taxane-refractory metastatic breast cancer.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine the acute side effects in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive R101933 IV over 1 hour immediately followed by paclitaxel IV over 3 hours or&#xD;
      docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 7 courses in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients who have no disease&#xD;
      progression after 7 courses may continue with treatment at the investigator's discretion.&#xD;
&#xD;
      Patients are followed every 6 weeks until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">35</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>laniquidar</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic breast cancer&#xD;
&#xD;
          -  Received at least 2 prior courses of paclitaxel-based chemotherapy at doses between&#xD;
             175-200 mg/m^2 (given over 3 hours every 3 weeks) or docetaxel-based chemotherapy at&#xD;
             doses between 75-100 mg/m^2 (given over 1 hour every 3 weeks) as most recent&#xD;
             anticancer therapy&#xD;
&#xD;
          -  Evidence of disease resistance&#xD;
&#xD;
               -  Progressive disease as best response OR&#xD;
&#xD;
               -  Transient response or disease stabilization followed by progression during&#xD;
                  taxane-based treatment&#xD;
&#xD;
               -  Disease progression on a combination of a taxane and another cytotoxic agent&#xD;
                  allowed&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
               -  At least 1 target lesion that clearly progressed or developed during prior taxane&#xD;
                  therapy&#xD;
&#xD;
               -  Lesions stable or responsive to prior taxane therapy are not considered target&#xD;
                  lesions&#xD;
&#xD;
               -  Lesions that have been irradiated within the past 3 months are not considered&#xD;
                  target lesions unless they have clearly progressed or appeared since radiotherapy&#xD;
&#xD;
          -  No bone metastases as only site of measurable disease&#xD;
&#xD;
          -  No rapidly progressive visceral metastases&#xD;
&#xD;
          -  No symptomatic CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF normal by echocardiogram (ECG) or MUGA scan&#xD;
&#xD;
          -  QTc less than 450 sec on baseline ECG&#xD;
&#xD;
          -  No prior clinically significant arrhythmias requiring treatment&#xD;
&#xD;
          -  No cardiac infarction&#xD;
&#xD;
          -  No atrial ventricular enlargement or hypertrophy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior toxicity to paclitaxel that would preclude study dose and schedule&#xD;
&#xD;
          -  Sodium, potassium, chloride, and bicarbonate normal&#xD;
&#xD;
          -  No pre-existing neuropathy greater than grade 2&#xD;
&#xD;
          -  No other prior or concurrent malignancy except adequately treated carcinoma in situ of&#xD;
             the cervix, contralateral breast cancer, or nonmelanoma skin cancer or cancer that has&#xD;
             been in remission for more than 5 years&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent anticancer biologic agents&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 8 weeks since last course of prior taxane-based chemotherapy&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for metastatic breast cancer&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior multi-drug resistance inhibitor&#xD;
&#xD;
          -  No new anticancer therapy initiation since last course of prior taxane-based&#xD;
             chemotherapy&#xD;
&#xD;
          -  No concurrent angiotensin converting enzyme inhibitor and/or drugs that may prolong&#xD;
             the QTc interval&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Concurrent bisphosphonates for treatment and prevention of bony metastases allowed&#xD;
             provided drugs were initiated prior to study (treatment of hypercalcemia due to&#xD;
             malignancy allowed regardless of time of initiation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernardo L. Rapoport, MD, MMed(IntMed)</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Oncology Centre of Rosebank</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Fumoleau, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martine J. Piccart-Gebhart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

